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Breast cancer frequently metastasises to the skeleton, interfering with the normal bone remodelling
process and inducing bone degradation. Bone degradation is caused by osteoclasts, the normal bone-
resorbing cells. Osteoclast-mediated bone degradation subsequently leads to the release of bone-derived
factors that promote skeletal tumour growth. Osteoclasts themselves stimulate tumour growth. This
Review describes the molecular mechanisms through which osteoclasts and breast cancer cells colla-
borate with each other, triggering the formation of osteolytic bone metastasis.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Once metastatic breast cancer cells are in the bone marrow,
they hijack signals coming from the normal bone remodelling
process and promote bone degradation [1]. Bone degradation is
caused by osteoclasts, which have the unique property to dissolve
bone mineral and degrade the bone matrix. These features make
them a predominant actor in bone metastasis formation. This re-
view describes how osteoclasts contribute to bone degradation
and skeletal tumour growth.2. Bone physiology
2.1. Osteoclastogenesis
Osteoclasts derive from haematopoietic stem cells. Osteoclast
differentiation is dependent on two key molecules, Macrophage
Colony Stimulating Factor (M-CSF) and Receptor activator of NFκB
ligand (RANKL), the latter being also a mediator of osteoclast
function and survival [2,3]. The stimulation of the RANK pathway
by RANKL is negatively regulated by a decoy receptor, osteopro-
tegerin (OPG), which is expressed by osteoblasts [3]. Others factors
that inﬂuence osteoclast formation are Tumour Necrosis Factors αGmbH. This is an open access art
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lézardin).(TNFα) [4] and interleukins (IL-1, IL-8, IL-11) [5].
2.2. Osteoclast-mediated bone resorption
Osteoclasts are the normal bone-resorbing cells. Osteoclast-
mediated bone resorption can be viewed as a sequential process
where dissolution of the mineral phase of bone precedes matrix
degradation. Bone demineralization involves the secretion of
protons by osteoclasts which, in turn, provide an optimal acidic
microenvironment for the proteolytic activity of osteoclast-de-
rived cathepsin K, enabling degradation of the demineralized
collagenous matrix [5]. Matrix metalloprotease MMP13 is also
involved in the degradation of the collagen matrix [6]. This de-
gradation leads to the release of calcium (Ca2þ) and of bone-de-
rived growth factors embedded within the bone matrix, such as
Transforming Growth Factor (TGFβ), Insulin Growth Factors (IGFs),
and Platelet derived growth factor (PDGF) [7].3. Osteolytic bone metastasis: the “Vicious Cycle”
Once metastatic cancer cells colonize bone, they do not, on
their own, destroy bone. They interact with osteoblasts, the nor-
mal bone-forming cells, and osteoclasts to induce massive bone
degradation. In turn, bone-derived growth factors and calcium
released from resorbed bone stimulate skeletal tumour growth.
This relationship between bone resorption and tumour growth is
called the “vicious cycle” (Fig. 1). This is the reason why anti-icle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Breast cancer bone metastasis formation. In bone, breast tumour cells se-
crete different factors that enhance osteoclast differentiation and activity (blue
arrows). Consequently, bone-resorbing activity of mature osteoclasts is increasing.
Bone-embedded growth factors, which are released from the bone matrix, and
miRNAs secreted by osteoclasts then promote tumour growth (green arrows). In
addition, tumour cells secrete factors (DKK-1, SOST) that inhibit osteoblast differ-
entiation and activity, thereby contributing to cancer-induced bone destruction
(red arrows).
F. Le Pape et al. / Journal of Bone Oncology 5 (2016) 93–9594resorptive drugs such as bisphosphonates and denosumab, a hu-
man monoclonal antibody directed against RANKL, are used in
clinic, as palliative treatment, to interfere with this vicious cycle
[8].
3.1. Tumour-derived factors that promote osteoclast-mediated bone
degradation
Several molecules that are produced by breast cancer cells,
such as interleukins (IL-8, IL-11), M-CSF, and TNFα directly sti-
mulate osteoclast activity [9]. Other factors including Parathyroid
Hormone-related Protein (PTHrP), interleukins (IL-1, and IL-6) and
prostaglandin E2 (PGE2) enhance osteoclast formation through the
regulation of RANKL/OPG production by osteoblasts [10]. In sum,
tumour cells produce a large panel of soluble factors that promote
bone degradation (Fig. 1). However, tumour cells may produce
factors that inhibit osteoclast activity [endothelin-1 (ET-1), OPG],
leading to the formation of osteoblastic or mixed lesions [11,12].
3.2. Tumour-derived factors that contribute to bone degradation
Cathepsin K is produced by tumour cells [13]. It promotes tu-
mour cell invasiveness and may also contribute to bone degrada-
tion [13]. In this respect, there is preclinical evidence that treat-
ment of animals bearing bone metastases with a cathepsin K in-
hibitor (odanacatib, AFG-495) partially blocks bone degradation
[13]. Additionally, a number of factors that inhibit osteoblast dif-
ferentiation [dickkopf-1 (DKK-1) and sclerostin (SOST)] have been
reported to be secreted by tumour cells [9]. By inhibiting bone
formation, DKK-1 and SOST will also indirectly contribute to bone
degradation (Fig. 1).
3.3. Osteoclast-derived factors that promote tumour growth
MicroRNAs (miRNAs) expressed by tumour cells can act as
master regulators of bone metastasis formation [14]. Although
osteoclasts are mostly known for being directly involved inmediating bone resorption, they also secrete miRNAs that mod-
ulate skeletal tumour growth [15,16] (Fig. 1). For example, osteo-
clasts secrete exosomes containing miRNAs such as miR-378
which promotes tumour growth, angiogenesis and tumour cell
survival through the repression of tumour suppressors SuFu and
Fus-1 [17]. Additionally, osteoclast-derived miR-21 enhances tu-
mour cell proliferation [18].
3.4. Factors released from resorbed bone that promote tumour
growth
Bone is a reservoir of growth factors and calcium capable of
stimulating growth of tumour cells (Fig. 1). Activated TGFβ sti-
mulates tumour growth and PTHrP expression by tumour cells,
which in turn stimulates osteoclast-mediated bone resorption
[19]. IGFs, PDGF and BMP (Bone Morphogenic Protein) family
members are also released from the bone matrix and they enhance
tumour cell proliferation [9]. Calcium acts on tumour cells ex-
pressing the calcium-sensing receptor (CASR) by enhancing tu-
mour cell survival [20].4. Conclusion
Current knowledge on the pathogenesis of bone metastasis
demonstrates that osteoclasts are playing a key role in mediating
bone degradation and promoting skeletal tumour growth. These
ﬁndings provide the rationale for using anti-resorptive drugs (bi-
sphosphonates, anti-RANKL) in the treatment of bone metastasis.
However, these molecules do not treat cancer but slow down its
progression by limiting the extent of bone destruction. Thus, it's
truly vital to increase our understanding of the cellular and mo-
lecular mechanisms that precede the overt development of ske-
letal lesions in order to develop novel therapeutic strategies.References
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